|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
US4326525A
(en)
|
1980-10-14 |
1982-04-27 |
Alza Corporation |
Osmotic device that improves delivery properties of agent in situ
|
|
US4816570A
(en)
|
1982-11-30 |
1989-03-28 |
The Board Of Regents Of The University Of Texas System |
Biologically reversible phosphate and phosphonate protective groups
|
|
US5364620A
(en)
|
1983-12-22 |
1994-11-15 |
Elan Corporation, Plc |
Controlled absorption diltiazem formulation for once daily administration
|
|
US5023252A
(en)
|
1985-12-04 |
1991-06-11 |
Conrex Pharmaceutical Corporation |
Transdermal and trans-membrane delivery of drugs
|
|
US4968788A
(en)
|
1986-04-04 |
1990-11-06 |
Board Of Regents, The University Of Texas System |
Biologically reversible phosphate and phosphonate protective gruops
|
|
US4992445A
(en)
|
1987-06-12 |
1991-02-12 |
American Cyanamid Co. |
Transdermal delivery of pharmaceuticals
|
|
US5001139A
(en)
|
1987-06-12 |
1991-03-19 |
American Cyanamid Company |
Enchancers for the transdermal flux of nivadipine
|
|
US4902514A
(en)
|
1988-07-21 |
1990-02-20 |
Alza Corporation |
Dosage form for administering nilvadipine for treating cardiovascular symptoms
|
|
EP0533833B1
(en)
|
1990-06-13 |
1995-12-20 |
GLAZIER, Arnold |
Phosphorous produgs
|
|
EP0481214B1
(en)
|
1990-09-14 |
1998-06-24 |
Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic |
Prodrugs of phosphonates
|
|
US5922695A
(en)
|
1996-07-26 |
1999-07-13 |
Gilead Sciences, Inc. |
Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
|
|
US5935946A
(en)
|
1997-07-25 |
1999-08-10 |
Gilead Sciences, Inc. |
Nucleotide analog composition and synthesis method
|
|
US20020119443A1
(en)
|
2000-07-21 |
2002-08-29 |
Gilead Sciences, Inc. |
Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
|
|
JP4357293B2
(ja)
|
2001-06-27 |
2009-11-04 |
スミスクライン ビーチャム コーポレーション |
ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
|
|
ATE380175T1
(de)
|
2001-06-27 |
2007-12-15 |
Smithkline Beecham Corp |
Pyrrolidine als dipeptidyl peptidase inhibitoren
|
|
ATE355064T1
(de)
|
2001-10-26 |
2006-03-15 |
Angeletti P Ist Richerche Bio |
Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
|
|
US7642277B2
(en)
|
2002-12-04 |
2010-01-05 |
Boehringer Ingelheim International Gmbh |
Non-nucleoside reverse transcriptase inhibitors
|
|
WO2004071448A2
(en)
|
2003-02-12 |
2004-08-26 |
Transtech Pharma Inc. |
Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
|
|
EA014685B1
(ru)
|
2003-04-25 |
2010-12-30 |
Джилид Сайэнс, Инк. |
Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
|
|
US7186747B2
(en)
|
2004-02-27 |
2007-03-06 |
Schering Corporation |
Compounds as inhibitors of hepatitis C virus NS3 serine protease
|
|
US7453002B2
(en)
|
2004-06-15 |
2008-11-18 |
Bristol-Myers Squibb Company |
Five-membered heterocycles useful as serine protease inhibitors
|
|
US7429604B2
(en)
|
2004-06-15 |
2008-09-30 |
Bristol Myers Squibb Company |
Six-membered heterocycles useful as serine protease inhibitors
|
|
AU2005330489B2
(en)
|
2004-07-27 |
2011-08-25 |
Gilead Sciences, Inc. |
Nucleoside phosphonate conjugates as anti HIV agents
|
|
TWI382019B
(zh)
|
2005-08-19 |
2013-01-11 |
Array Biopharma Inc |
作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
|
|
TW201402124A
(zh)
|
2005-08-19 |
2014-01-16 |
Array Biopharma Inc |
作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
|
|
NZ568595A
(en)
|
2005-12-14 |
2010-04-30 |
Bristol Myers Squibb Co |
Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
|
|
EP2010493B1
(en)
|
2006-04-12 |
2016-01-27 |
Merck Sharp & Dohme Corp. |
Pyridyl amide t-type calcium channel antagonists
|
|
PL2049506T5
(pl)
|
2006-07-07 |
2024-09-09 |
Gilead Sciences, Inc. |
Modulatory farmakokinetycznych właściwości leków
|
|
WO2008013622A2
(en)
|
2006-07-27 |
2008-01-31 |
E. I. Du Pont De Nemours And Company |
Fungicidal azocyclic amides
|
|
US8193225B2
(en)
|
2006-10-13 |
2012-06-05 |
The Board Of Regents Of The University Of Texas System |
Isoxazole amides, derivatives and methods of chemical induction of neurogenesis
|
|
US8124811B2
(en)
|
2007-03-20 |
2012-02-28 |
Allylix, Inc. |
Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one
|
|
EP2139883A4
(en)
|
2007-03-23 |
2011-06-22 |
Univ Massachusetts |
HIV-1 protease inhibitor
|
|
CA2691444C
(en)
|
2007-06-29 |
2016-06-14 |
Gilead Sciences, Inc. |
Purine derivatives and their use as modulators of toll-like receptor 7
|
|
WO2009005677A2
(en)
|
2007-06-29 |
2009-01-08 |
Gilead Sciences, Inc. |
Antiviral compounds
|
|
CA2693044C
(en)
|
2007-07-12 |
2017-03-14 |
Tibotec Pharmaceuticals |
Crystalline form of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
|
|
AU2008277377B2
(en)
|
2007-07-19 |
2013-08-01 |
Msd Italia S.R.L. |
Macrocyclic compounds as antiviral agents
|
|
AU2008317353B2
(en)
|
2007-10-24 |
2014-08-07 |
Merck Sharp & Dohme Llc |
Heterocycle phenyl amide T-type calcium channel antagonists
|
|
JP2011500808A
(ja)
|
2007-10-24 |
2011-01-06 |
メルク・シャープ・エンド・ドーム・コーポレイション |
複素環アミドｔ型カルシウムチャネルアンタゴニスト
|
|
EA019259B1
(ru)
|
2007-11-16 |
2014-02-28 |
Джилид Сайенсиз, Инк. |
Ингибиторы репликации вируса иммунодефицита человека
|
|
US8324199B2
(en)
|
2008-03-13 |
2012-12-04 |
Bristol-Myers Squibb Company |
Pyridazine derivatives as factor xia inhibitors
|
|
HUE025528T2
(en)
|
2008-04-23 |
2016-05-30 |
Gilead Sciences Inc |
1'-substituted carba-nucleoside analogs for antiviral treatment
|
|
WO2010014913A1
(en)
|
2008-08-01 |
2010-02-04 |
Ventirx Pharmaceuticals, Inc. |
Toll-like receptor agonist formulations and their use
|
|
GB0817207D0
(en)
|
2008-09-19 |
2008-10-29 |
Pimco 2664 Ltd |
therapeutic apsac compounds and their use
|
|
RS53347B
(sr)
|
2008-12-09 |
2014-10-31 |
Gilead Sciences, Inc. |
Modulatori toll-sličnih receptora
|
|
CN102414217A
(zh)
|
2009-02-25 |
2012-04-11 |
彼格泰格私人有限公司 |
用于检测基孔肯雅病毒的探针和引物
|
|
US8673307B1
(en)
|
2009-03-09 |
2014-03-18 |
The Rockefeller University |
HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120
|
|
US8338441B2
(en)
|
2009-05-15 |
2012-12-25 |
Gilead Sciences, Inc. |
Inhibitors of human immunodeficiency virus replication
|
|
CN105669553A
(zh)
|
2009-08-18 |
2016-06-15 |
文蒂雷克斯药品公司 |
作为toll样受体调节剂的取代的苯并氮杂*
|
|
RU2016108987A
(ru)
|
2009-08-18 |
2018-11-26 |
Вентиркс Фармасьютикалз, Инк. |
Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора
|
|
JP5694345B2
(ja)
|
2009-10-22 |
2015-04-01 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｔｏｌｌ様受容体の調節因子
|
|
US20110274648A1
(en)
|
2009-11-11 |
2011-11-10 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
|
TWI508726B
(zh)
|
2009-12-21 |
2015-11-21 |
Gilead Sciences Inc |
治療心房纖維性顫動之方法
|
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
|
WO2011139637A1
(en)
|
2010-05-03 |
2011-11-10 |
Philadelphia Health & Education Corporation |
Small-molecule modulators of hiv-1 capsid stability and methods thereof
|
|
US20130053381A1
(en)
|
2010-05-20 |
2013-02-28 |
Novartis Ag |
2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl-sulfonamide derivatives
|
|
WO2011143772A1
(en)
|
2010-05-21 |
2011-11-24 |
Boehringer Ingelheim International Gmbh |
Inhibitors of hiv replication
|
|
MX2012015097A
(es)
|
2010-07-02 |
2013-05-28 |
Gilead Sciences Inc |
Derivados de acido naft-2-ilacetico para tratar sida.
|
|
EP2588455B1
(en)
|
2010-07-02 |
2018-04-04 |
Gilead Sciences, Inc. |
2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
|
|
ES2524356T3
(es)
|
2010-07-22 |
2014-12-05 |
Gilead Sciences, Inc. |
Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
|
|
WO2012020301A2
(en)
|
2010-08-10 |
2012-02-16 |
Lupin Limited |
Oral controlled release pharmaceutical compositions of blonanserin
|
|
EP3195868A3
(en)
|
2010-10-01 |
2017-08-02 |
VentiRx Pharmaceuticals, Inc. |
Therapeutic use of a tlr agonist and combination therapy
|
|
CN103237549A
(zh)
|
2010-10-01 |
2013-08-07 |
帆德制药股份有限公司 |
过敏性疾病的治疗方法
|
|
CN102464654B
(zh)
|
2010-11-12 |
2016-01-13 |
上海泓博智源医药技术有限公司 |
抗病毒化合物
|
|
DK2663555T3
(en)
|
2011-01-12 |
2017-03-27 |
Ventirx Pharmaceuticals Inc |
SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
|
|
EP3208263A1
(en)
|
2011-01-12 |
2017-08-23 |
VentiRx Pharmaceuticals, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
|
SI2688403T1
(sl)
|
2011-03-23 |
2017-08-31 |
Trevena, Inc. |
Ligandi opioidnih receptorjev in metode uporabe in izdelave istega
|
|
PT3590928T
(pt)
|
2011-04-08 |
2021-08-19 |
Janssen Sciences Ireland Unlimited Co |
Derivados de pirimidina para o tratamento de infeções virais
|
|
UA111841C2
(uk)
|
2011-04-21 |
2016-06-24 |
Гіліад Сайєнсіз, Інк. |
Сполуки бензотіазолу та їх фармацевтичне застосування
|
|
WO2012154312A1
(en)
|
2011-05-09 |
2012-11-15 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Neutralizing antibodies to hiv-1 and their use
|
|
CN103797029B
(zh)
|
2011-05-17 |
2016-08-17 |
洛克菲勒大学 |
人类免疫缺陷病毒中和抗体及其使用方法
|
|
AU2012258220B2
(en)
|
2011-05-18 |
2017-01-19 |
Janssen Sciences Ireland Uc |
Quinazoline derivatives for the treatment of viral infections and further diseases
|
|
AU2012278976B2
(en)
|
2011-07-06 |
2017-05-11 |
Gilead Sciences, Inc. |
Compounds for the treatment of HIV
|
|
CN102863512B
(zh)
|
2011-07-07 |
2016-04-20 |
上海泓博智源医药技术有限公司 |
抗病毒化合物
|
|
US9493549B2
(en)
|
2011-07-25 |
2016-11-15 |
The Rockefeller University |
Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
|
|
ES2608871T5
(es)
|
2011-08-16 |
2024-04-04 |
Gilead Sciences Inc |
Alafenamide hemifumarate de tenofovir
|
|
EP2788376B1
(en)
|
2011-12-08 |
2018-10-03 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Neutralizing antibodies to hiv-1 and their use
|
|
US9399645B2
(en)
|
2011-12-20 |
2016-07-26 |
Boehringer Ingelheim International Gmbh |
Inhibitors of HIV replication
|
|
BR112014015197A8
(pt)
|
2011-12-21 |
2017-06-13 |
Novira Therapeutics Inc |
agentes antivirais de hepatite b
|
|
SG11201404743TA
(en)
|
2012-02-08 |
2014-09-26 |
Janssen R & D Ireland |
Piperidino-pyrimidine derivatives for the treatment of viral infections
|
|
RU2014140177A
(ru)
|
2012-03-05 |
2016-04-27 |
Сипла Лимитед |
Фармацевтические антиретровирусные композиции
|
|
US20150044137A1
(en)
|
2012-03-23 |
2015-02-12 |
The United States of America, as represented by the Secretary, Dep. of Health Care Human Services |
Neutralizing antibodies to hiv-1 and their use
|
|
UY34750A
(es)
|
2012-04-20 |
2013-11-29 |
Gilead Sciences Inc |
?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
|
|
GB201213087D0
(en)
|
2012-07-24 |
2012-09-05 |
Medical Res Council |
Inhibition of HIV-1 infection
|
|
MX369417B
(es)
|
2012-08-10 |
2019-11-07 |
Janssen Sciences Ireland Uc |
Derivados de alquilpirimidina para el tratamiento de infecciones víricas y otras enfermedades.
|
|
WO2014028931A2
(en)
|
2012-08-17 |
2014-02-20 |
Brandeis University |
Compounds and methods for treating mammalian gastrointestinal microbial infections
|
|
DK2906563T3
(en)
|
2012-10-10 |
2018-06-06 |
Janssen Sciences Ireland Uc |
PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND OTHER DISEASES
|
|
CN118955699A
(zh)
|
2012-10-18 |
2024-11-15 |
洛克菲勒大学 |
广泛中和性抗hiv抗体
|
|
EA035431B1
(ru)
|
2012-11-16 |
2020-06-15 |
Янссен Сайенсиз Айрлэнд Юси |
Гетероциклические замещенные производные 2-амино-хиназолина в качестве модуляторов tlr7 и/или tlr8 для лечения вирусных инфекций
|
|
WO2014089152A1
(en)
|
2012-12-04 |
2014-06-12 |
University Of Maryland, Baltimore |
Hiv-1 env-binding antibodies, fusion proteins, and methods of use
|
|
EA030003B1
(ru)
|
2012-12-21 |
2018-06-29 |
Джилид Сайэнс, Инк. |
Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
|
|
PE20151063A1
(es)
|
2012-12-27 |
2015-08-03 |
Japan Tobacco Inc |
DERIVADO SUSTITUIDO DE ESPIROPIRIDO[1,2-a]PIRAZINA Y USO MEDICO DEL MISMO COMO INHIBIDOR DE LA INTEGRASA DEL VIH
|
|
US9220710B2
(en)
|
2013-01-09 |
2015-12-29 |
Gilead Sciences, Inc. |
Therapeutic compounds
|
|
ES2642265T3
(es)
|
2013-01-09 |
2017-11-16 |
Gilead Sciences, Inc. |
Compuestos terapéuticos para el tratamiento de infecciones virales
|
|
TW201443037A
(zh)
|
2013-01-09 |
2014-11-16 |
Gilead Sciences Inc |
治療用化合物
|
|
WO2014110323A1
(en)
|
2013-01-11 |
2014-07-17 |
Johnson Controls Technology Company |
Vehicle interior component having a wireless charging indicator
|
|
SG11201506639XA
(en)
|
2013-02-21 |
2015-09-29 |
Janssen Sciences Ireland Uc |
2-aminopyrimidine derivatives for the treatment of viral infections
|
|
EP2769722A1
(en)
|
2013-02-22 |
2014-08-27 |
Ruprecht-Karls-Universität Heidelberg |
Compounds for use in inhibiting HIV capsid assembly
|
|
US20140296266A1
(en)
|
2013-03-01 |
2014-10-02 |
Gilead Sciences, Inc. |
Therapeutic compounds
|
|
TWI694071B
(zh)
|
2013-03-01 |
2020-05-21 |
美商基利科學股份有限公司 |
治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
|
|
US8993771B2
(en)
|
2013-03-12 |
2015-03-31 |
Novira Therapeutics, Inc. |
Hepatitis B antiviral agents
|
|
GB201312991D0
(en)
|
2013-07-19 |
2013-09-04 |
Isis Innovation |
Process
|
|
US20160244510A1
(en)
|
2013-09-27 |
2016-08-25 |
Duke University |
Human monoclonal antibodies
|
|
AU2014340110B2
(en)
|
2013-10-24 |
2018-07-12 |
VIIV Healthcare UK (No.5) Limited |
Inhibitors of human immunodeficiency virus replication
|
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
WO2015117008A2
(en)
|
2014-01-31 |
2015-08-06 |
The Rockefeller University |
Broadly neutralizing anti-hiv antibodies and epitope therefor
|
|
US10202353B2
(en)
|
2014-02-28 |
2019-02-12 |
Gilead Sciences, Inc. |
Therapeutic compounds
|
|
WO2015130966A1
(en)
|
2014-02-28 |
2015-09-03 |
Gilead Sciences, Inc. |
Antiviral agents
|
|
NO2717902T3
(https=)
|
2014-06-20 |
2018-06-23 |
|
|
|
WO2016014484A1
(en)
|
2014-07-21 |
2016-01-28 |
The Rockefeller University |
Combination of broadly neutralizing hiv antibodies and viral inducers
|
|
EP3186239B1
(en)
|
2014-08-29 |
2018-10-10 |
Gilead Sciences, Inc. |
Antiretroviral agents
|
|
US9855230B2
(en)
|
2014-09-09 |
2018-01-02 |
VIIV Healthcare UK (No.5) Limited |
Inhibitors of human immunodeficiency virus replication
|
|
TWI699355B
(zh)
|
2014-12-24 |
2020-07-21 |
美商基利科學股份有限公司 |
喹唑啉化合物
|
|
BR112017013440A2
(pt)
|
2014-12-24 |
2018-01-09 |
Gilead Sciences, Inc. |
compostos de isoquinolina para o tratamento de hiv
|
|
SG11201705192PA
(en)
|
2014-12-24 |
2017-07-28 |
Gilead Sciences Inc |
Fused pyrimidine compounds for the treatment of hiv
|
|
US9670205B2
(en)
|
2015-03-04 |
2017-06-06 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
|
US11071783B2
(en)
|
2015-03-19 |
2021-07-27 |
Duke University |
HIV-1 neutralizing antibodies and uses thereof
|
|
ES2789348T3
(es)
|
2015-03-20 |
2020-10-26 |
Us Health |
Anticuerpos neutralizantes para GP120 y sus usos
|
|
WO2016172425A1
(en)
|
2015-04-23 |
2016-10-27 |
Viiv Healthcare (No.5) Limited |
Inhibitors of human immunodeficiency virus replication
|
|
US10221129B2
(en)
|
2015-04-23 |
2019-03-05 |
VIIV Healthcare UK (No.5) Limited |
Inhibitors of human immunodeficiency virus replication
|
|
SG11201708804WA
(en)
|
2015-05-07 |
2017-11-29 |
Agenus Inc |
Anti-ox40 antibodies and methods of use thereof
|
|
WO2016196975A1
(en)
|
2015-06-03 |
2016-12-08 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
PL3456717T3
(pl)
|
2015-07-06 |
2021-10-25 |
Gilead Sciences, Inc. |
Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej
|
|
US10071885B2
(en)
|
2015-08-26 |
2018-09-11 |
Gerard O'Brien |
Vacuum lift attachment
|
|
CA2997955A1
(en)
|
2015-09-15 |
2017-03-23 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors for the treatment of hiv
|
|
WO2017096276A1
(en)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Anti-gitr antibodies and methods of use thereof
|
|
MA43389A
(fr)
|
2015-12-02 |
2021-05-12 |
Agenus Inc |
Anticorps anti-ox40 et leurs procédés d'utilisation
|
|
CN108883173B
(zh)
|
2015-12-02 |
2022-09-06 |
阿吉纳斯公司 |
抗体和其使用方法
|
|
WO2017096221A1
(en)
|
2015-12-02 |
2017-06-08 |
The Rockefeller University |
Bispecific anti-hiv broadly neutralizing antibodies
|
|
EP3383431A4
(en)
|
2015-12-02 |
2019-08-28 |
Agenus Inc. |
ANTI-GITR ANTIBODIES AND METHOD OF USE THEREOF
|
|
AU2016364891A1
(en)
|
2015-12-03 |
2018-06-07 |
Agenus Inc. |
Anti-OX40 antibodies and methods of use thereof
|
|
JP6732915B2
(ja)
|
2015-12-15 |
2020-07-29 |
ギリアード サイエンシーズ， インコーポレイテッド |
ヒト免疫不全ウイルス中和抗体
|
|
KR102659250B1
(ko)
|
2015-12-28 |
2024-04-22 |
노보자임스 바이오아게 에이/에스 |
안정한 접종제 조성물 및 그의 생성 방법
|
|
CN107022027B
(zh)
|
2016-02-02 |
2022-03-08 |
中国疾病预防控制中心性病艾滋病预防控制中心 |
Hiv-1广谱中和抗体及其用途
|
|
CN107033241B
(zh)
|
2016-02-03 |
2022-03-08 |
中国疾病预防控制中心性病艾滋病预防控制中心 |
Hiv-1广谱中和抗体及其用途
|
|
CN119462611A
(zh)
|
2016-08-19 |
2025-02-18 |
吉利德科学公司 |
用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
|
|
AU2017318601B2
(en)
|
2016-09-02 |
2020-09-03 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
|
WO2018045150A1
(en)
|
2016-09-02 |
2018-03-08 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
|
MA46770A
(fr)
|
2016-11-09 |
2019-09-18 |
Agenus Inc |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|
|
AR110922A1
(es)
|
2017-02-06 |
2019-05-15 |
Gilead Sciences Inc |
Compuestos inhibidores del vih
|
|
TW201906834A
(zh)
|
2017-05-02 |
2019-02-16 |
英商Viiv醫療保健英國(No.5)有限公司 |
人類免疫不全病毒複製之抑制劑
|
|
AR112257A1
(es)
|
2017-06-21 |
2019-10-09 |
Gilead Sciences Inc |
Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos
|
|
TWI687415B
(zh)
|
2017-08-17 |
2020-03-11 |
美商基利科學股份有限公司 |
Hiv蛋白質膜抑制劑之固體形式
|
|
AR112412A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas de sal de colina de un inhibidor de la cápside del vih
|
|
JOP20180092A1
(ar)
|
2017-10-13 |
2019-04-13 |
Gilead Sciences Inc |
مثبطات hiv بروتياز
|
|
AU2018354423B2
(en)
|
2017-10-27 |
2024-11-07 |
Plexxikon Inc. |
Formulations of a compound modulating kinases
|
|
WO2019087016A1
(en)
|
2017-10-30 |
2019-05-09 |
Glaxosmithkline Intellectual Property Development Limited |
Compounds useful in hiv therapy
|
|
JP7083398B2
(ja)
|
2018-02-15 |
2022-06-10 |
ギリアード サイエンシーズ， インコーポレイテッド |
ピリジン誘導体およびｈｉｖ感染を処置するためのその使用
|
|
EP3752496B1
(en)
|
2018-02-16 |
2023-07-05 |
Gilead Sciences, Inc. |
Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
|
|
US10911396B2
(en)
|
2018-06-28 |
2021-02-02 |
Paypal, Inc. |
Mid-tier messaging system
|
|
DK4257600T3
(da)
|
2018-07-03 |
2025-05-26 |
Gilead Sciences Inc |
Antistoffer rettet mod hiv gp120 og fremgangsmåder til at bruge dem
|
|
KR20210033492A
(ko)
|
2018-07-16 |
2021-03-26 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv의 치료를 위한 캡시드 억제제
|
|
TWI829205B
(zh)
|
2018-07-30 |
2024-01-11 |
美商基利科學股份有限公司 |
抗hiv化合物
|
|
MY201239A
(en)
|
2019-03-22 |
2024-02-13 |
Gilead Sciences Inc |
Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
|
|
CA3157275C
(en)
|
2019-11-26 |
2026-02-10 |
Gilead Sciences, Inc. |
Capsid inhibitors for the prevention of hiv
|
|
TWI858267B
(zh)
|
2020-06-25 |
2024-10-11 |
美商基利科學股份有限公司 |
用於治療hiv之蛋白殼抑制劑
|
|
CR20240223A
(es)
|
2021-12-03 |
2024-07-08 |
Gilead Sciences Inc |
Compuestos terapéuticos para la infección por el virus del vih
|
|
US20240390349A1
(en)
|
2023-04-19 |
2024-11-28 |
Gilead Sciences, Inc. |
Dosing regimen of capsid inhibitor
|